Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Merck Breaks Ground on $162 Million Hangzhou Facility

publication date: Jul 13, 2010
Merck Sharp & Dohme, the international arm of the US big pharma Merck, started construction of a 1.1 billion RMB ($162 million) pharmaceutical packaging plant in the Hangzhou Economic and Technological Area. Underscoring the global significance of the move, Merck last week announced the closing of 16 facilities in other parts of the world. Eight of those soon-to-be-closed sites are manufacturing plants. More details....

Stock Symbol: (NYSE: MRK)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital